Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 3
1975 1
1976 2
1977 1
1980 2
1981 2
1982 3
1983 4
1984 6
1985 2
1986 2
1987 4
1988 1
1989 2
1990 3
1991 2
1992 7
1993 2
1994 8
1995 2
1996 3
1997 1
1998 1
1999 3
2000 1
2003 1
2005 1
2006 1
2007 1
2008 5
2013 1
2014 1
2015 1
2016 1
2018 3
2019 3
2020 3
2021 5
2022 1
2023 7
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC; MENTOR Investigators. Fervenza FC, et al. Among authors: philibert d. N Engl J Med. 2019 Jul 4;381(1):36-46. doi: 10.1056/NEJMoa1814427. N Engl J Med. 2019. PMID: 31269364 Clinical Trial.
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators. Barbour SJ, et al. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1283-1293. doi: 10.2215/CJN.0000000000000237. Epub 2023 Jul 20. Clin J Am Soc Nephrol. 2023. PMID: 37471101 Free PMC article.
RU 486.
Ulmann A, Teutsch G, Philibert D. Ulmann A, et al. Among authors: philibert d. Sci Am. 1990 Jun;262(6):42-8. doi: 10.1038/scientificamerican0690-42. Sci Am. 1990. PMID: 2343294
RU 486 development.
Philibert D, Teutsch G. Philibert D, et al. Science. 1990 Feb 9;247(4943):622. doi: 10.1126/science.2300819. Science. 1990. PMID: 2300819 No abstract available.
Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial.
Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo K, Barratt J; SANCTUARY Study Investigators. Lafayette R, et al. J Am Soc Nephrol. 2024 Oct 25. doi: 10.1681/ASN.0000000534. Online ahead of print. J Am Soc Nephrol. 2024. PMID: 39455063 No abstract available.
Pembrolizumab-Induced Anti-GBM Glomerulonephritis: A Case Report.
El Yamani N, Cote G, Riopel J, Marcoux N, Mac-Way F, Philibert D, Agharazii M. El Yamani N, et al. Among authors: philibert d. Kidney Med. 2023 May 30;5(8):100682. doi: 10.1016/j.xkme.2023.100682. eCollection 2023 Aug. Kidney Med. 2023. PMID: 37415622 Free PMC article.
106 results